Vytorin, Zetia Disappoint Again
Vytorin, Zetia Disappoint Vytorin and Zetia, Merck & Co.'s anti-cholesterol medications, are coming under fire again. A new study has found that a much older - and cheaper - drug reduced artery plaque much better in eight months than ezetimibe, the active ingredient in both Vytorin and Zetia. According to USA Today, this … [Read more...]
FDA Issues Vytorin Early Communication
FDA Reviews Vytorin. The Food & Drug Administration (FDA) weighed in on the Vytorin controversy today by issuing an Early Communication about its ongoing reviews of Vytorin, Zetia and Zocor. The FDA communication was prompted by preliminary results of the ENHANCE study that showed Vytorin was no better at preventing plaque … [Read more...]